FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an anti-CLDN18.2 antibody or its antigen-binding fragment, as well as to a pharmaceutical composition, a conjugate and a kit containing it. Also disclosed is an isolated polynucleotide coding said antibody or its fragment, as well as a vector and a cell containing it.
EFFECT: invention is effective for treating a disease or condition associated with CLDN18.2.
27 cl, 43 dwg, 27 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| THERAPY FOR TREATING CANCER, INCLUDING ANTIBODIES AGAINST CLAUDIN 18.2 | 2014 |
|
RU2832015C2 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
